SCHEMBL1342826

SCHEMBL1342826

Cc1ccc(N(C(=O)CC(=O)Nc2nc(CC(=O)O)c(Sc3ccccn3)s2)C(=O)C2CCCC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPT P10636 6/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
NPC1 O15118 3/20 0.35
GRM4 Q14833 2/20 0.33
ALDH1A1 P00352 4/20 0.33
ADORA3 P0DMS8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 3/20 0.33
OPRK1 P41145 1/20 0.33
HTT P42858 1/20 0.33
TP53 P04637 1/20 0.32
GLS O94925 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GFER P55789 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343437 0.95 GCK (0.39) GCKKMT2AMEN1MAPTRAB9A
SCHEMBL1341483 0.90 GCK (0.37) GCKKMT2AMEN1TDP1MAPT
SCHEMBL1342692 0.86 MAPT (0.37) KMT2AMEN1TDP1MAPTRAB9A
SCHEMBL1343045 0.86 MAPT (0.34) GCKKMT2AMEN1MAPTLMNA
SCHEMBL1342545 0.84 GCK (0.39) GCKKMT2AMEN1MAPTRAB9A
SCHEMBL1342700 0.83 MAPT (0.37) KMT2AMEN1MAPTRAB9ASMN1; SMN2
SCHEMBL1343221 0.82 GCK (0.47) GCKMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL1340015 0.81 MAPT (0.33) KMT2AMEN1TDP1MAPTRAB9A
SCHEMBL1342771 0.81 GCK (0.38) GCKKMT2AMEN1TDP1MAPT
SCHEMBL1342674 0.81 MAPT (0.37) KMT2AMEN1TDP1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 GCK 1/4885KMT2A 1526/4885MEN1 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.